Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A Pocket-Sized coach for sickle cell: can an app turn Pill-Taking into a habit?

NCT ID NCT04691323

Disease control Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This study follows adolescents and young adults (ages 12–21) with sickle cell disease who take hydroxyurea, a medication that helps prevent pain crises and other complications. The researchers are testing whether a mobile app called HU-Go can help these patients build a consistent medication habit and improve their quality of life. Over time, they will track how closely participants stick to their hydroxyurea schedule and measure any changes in pain, daily functioning, and overall well-being. The goal is to understand what helps or hinders medication adherence in this age group, so that better support tools can be developed.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HU-Go mobile app designed to support adherence to hydroxyurea medication
What this could lead to
If the app helps young people take hydroxyurea more consistently, it could point toward a simple digital tool to improve quality of life and reduce complications in sickle cell disease.
What could go wrong
This is an early, observational study, so it cannot prove the app causes better adherence or health outcomes. Results may not apply to all patients, and the app's effectiveness depends on real-world usage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

68 people

The number who actually took part.

Started

Mar 2021

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 21 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 12-21 years old * Any sickle cell disease genotype * On steady state of hydroxyurea for 2 months * Own or have access to a smartphone * Parents of patients that meet the eligibility criteria and are enrolled in the study will be included Exclusion Criteria: * Patients with recent hospitalizations within the past 7 days

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sickle B+ thalassemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hemoglobin SC Disease sickle cell disease sickle cell-beta plus-thalassemia sickle cell-beta zero-thalassemia sickle cell-hemoglobin c disease syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sickle B+ thalassemia Sickle beta zero thalassemia Sickle cell disease Sickle cell hemoglobin C

Contacts and locations

Locations

  • Ann & Robert H Lurie Children's Hospital of Chicago

    Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.